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ABSTRACT
Background: Amuvatinib (MP-470) is a multi-targeted kinase inhibitor with 
potent activity against c-Kit, synergistic with DNA-damaging agents. We evaluated 
amuvatinib in combination with platinum-etoposide (EP) chemotherapy by objective 
response rate, survival, and tolerability in platinum-refractory small cell lung cancer 
(SCLC) patients.
Methods: This study used a Simon 2-stage design requiring ≥3 centrally confirmed 
responses in the first 21 subjects. Subjects received EP with 300 mg amuvatinib orally 
three times daily in cycles of 21 days. A three-day amuvatinib run-in period before 
EP occurred in Cycle 1. Subjects received the same EP chemotherapy regimen given 
prior to progression/relapse.
Results: Among 23 subjects treated, we observed four PRs (17.4%) per RECIST 
1.1, only two of which were centrally confirmed (8.7%, response duration 119, 151 
days). Three subjects (13%) had confirmed stable disease. c-Kit H-score was ≥100 in 
two subjects whose respective durations of disease control were 151 and 256 days.
Conclusions: The addition of amuvatinib to EP chemotherapy in unselected, 
platinum-refractory SCLC did not meet the primary endpoint of ≥3 confirmed 
responses in stage 1. However, high c-Kit expression in two subjects with durable 
disease control suggests the potential for further study of amuvatinib in SCLC patients 
with high c-Kit expression.
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INTRODUCTION
Small cell lung cancer (SCLC) accounts for 13% 
of lung cancers diagnosed in the United States and is 
characterized by aggressive behavior with a high growth 
fraction and swift development of metastasis [1, 2]. 
Approximately 60%-70% of patients present with extensive-
stage SCLC and inevitably relapse despite initial response to 
chemotherapy and radiation. As a result, the median survival 
rate for these patients is only 8-13 months [3, 4]. Early 
diagnosis of SCLC and effective treatment remain significant 
challenges in the management of these patients.
In patients with extensive-stage disease, treatment with 
platinum-etoposide (EP) (cisplatin-etoposide or carboplatin-
etoposide) is an established and widely used first-line 
therapy [5, 4]. In those who experience a complete response 
(CR), partial response (PR), or who have stable disease 
(SD), treatment is usually discontinued after 4-6 cycles of 
chemotherapy. Extended treatment regimens increase toxicity 
and fail to prolong overall survival [5, 4]. Platinum-refractory 
patients (i.e. patients who progress while on EP or within 3 
months of completing first-line EP) have a guarded prognosis 
and are typically refractory to additional chemotherapy. For 
example, topotecan—the only FDA-approved chemotherapy 
for the second-line treatment of SCLC—has shown extremely 
limited activity in platinum-refractory SCLC, with an overall 
response rate of 6.4% [6]. Therefore, patients with platinum-
refractory have limited options.
Amuvatinib (MP-470) is a multi-targeted tyrosine 
kinase inhibitor with potent activity against several validated 
cancer targets, including mutant forms of c-Kit and platelet-
derived growth factor receptor alpha [7], and has been 
shown to have synergistic activity with DNA-damaging 
agents, including radiation and topoisomerase inhibitors 
[8]. The mechanism of action of amuvatinib is postulated 
to be DNA repair inhibition mediated by down regulation 
of RAD51 expression [8]. RAD51 is a key protein in the 
repair pathway for DNA double-strand breaks; it has been 
shown to be critical to the homologous recombination repair 
process in cells and can be employed as a mechanism of 
resistance to DNA-damaging agents in tumor cells. RAD51 
down regulation after amuvatinib treatment was associated 
with reduced ribosomal protein S6 phosphorylation and 
inhibition of global translation [9]. Hansen et al [10] have 
shown that etoposide resistance in SCLC cells is positively 
correlated with RAD51 levels and have suggested that 
RAD51 is a potential target to improve etoposide efficacy 
in treatment of SCLC. Previous preclinical studies have 
shown that amuvatinib in combination with etoposide has 
a synergistic effect on human SCLC cell lines in vitro and 
SCLC xenografts in vivo [11].
Phase 1 clinical studies have shown single-agent 
amuvatinib to be safe and well tolerated [12, 13], with 
amuvatinib exposures significantly improved when lipid-
suspension capsules rather than dry-powder capsules are 
administered [12]. In addition, Mita et al [14] showed 
preliminary evidence of anti-tumor activity and durable SD 
(up to 708 days) with amuvatinib administered at varying 
dose levels in combination with standard chemotherapy 
agents. This included a SCLC patient who had a partial 
response to amuvatinib in combination with carboplatin-
etoposide following multiple prior lines of chemotherapy.
In this ESCAPE study (TrEatment of Small Cell Lung 
Cancer with Amuvatinib in Combination with Platinum 
Etoposide), we sought to assess the effect of amuvatinib 
in combination with EP on the objective response rate in 
subjects with extensive-stage or limited-stage SCLC who 
had not responded to standard treatment with EP or who had 
relapsed within 90 days of EP treatment.
RESULTS
Enrollment and subject disposition
The study enrolled 24 subjects between September 
2011 and May 2012. Enrollment was concluded after 
Stage 1, as independent assessment showed that among the 
first 21 subjects, fewer than 3 had a confirmed response.
Of the 24 subjects enrolled, 23 (96%) received 
amuvatinib + EP and were included in the analysis (one subject 
was not treated because of abnormally high magnesium 
levels). Eleven (46%) were withdrawn from the study due 
to progressive disease, 4 (17%) withdrew due to an adverse 
event (AE), 3 (13%) withdrew consent, 3 (13%) withdrew 
due to death, and 3 (13%) withdrew due to physician decision.
Demographics and baseline characteristics
Table 1 shows subject demographics (N = 23). Mean 
age was 62 years (range, 44-80 years), and 87% were 
Caucasian. Twenty-two subjects (96%) had extensive-
stage disease, 1 (4%) had limited-stage disease, and the 
number of prior anticancer regimens ranged from one 
to three. The best response to prior therapy was partial 
response in 7 subjects (30%) and stable disease in 11 
(48%). Two subjects had disease progression after prior 
therapy with carboplatin/etoposide and had a best response 
of progressive disease in this study. The most frequently 
given prior chemotherapy was carboplatin/etoposide 
(16/23 subjects, or 70%) (Table 2); six subjects received 
cisplatin/etoposide and one received carboplatin/etoposide 
for cycle 1 and cisplatin/etoposide for cycles 2, 3, and 4. 
Subjects began amuvatinib treatment with the same dose 
and schedule of their last EP chemotherapy regimen in 
which they progressed or relapsed (Table 3).
Best response to treatment
Table 4 summarizes best response to treatment. 
Overall objective response rate (ORR) based on 
investigator assessment was four partial responses (PR) 
(17.4%) among the 23 subjects treated (95% CI: 5.0, 
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38.8). The primary endpoint of confirmed response by 
central assessment in evaluable subjects was 2/22 or 9% 
(95% CI: 1.1, 29.2); these two subjects were among the 
four who had a PR by investigator assessment. Figure 1 
shows best change from baseline in subjects’ target tumor.
Confirmed responders
Subject 001, a 67-yr-old female who had a best 
response of stable disease (duration unknown) with prior 
carboplatin/etoposide, had a confirmed PR of 119 days in 
this study. At baseline, her sum of tumor lesions measured 
68.0 mm, and after Cycle 6 a 52% decrease in tumor 
lesion sum to 33.0 mm was observed (Figure 2A).
Subject 023, a 52-yr-old male who had a best 
response of stable disease (4 months) with prior cisplatin/
etoposide, had a confirmed PR of 151 days (4.96 months) 
in this study. At baseline, his sum of tumor lesions was 
48.3 mm, and after Cycle 6 a 66% decrease to 16.5 mm 
was observed (Figure 2B).
Unconfirmed responders
Subject 002, a 44-year-old female whose best response 
to prior treatment is unknown, had a PR (by investigator 
assessment) of 21 days after Cycle 2; at baseline, her sum of 
tumor lesions measured 149.0 mm, and after Cycle 2 a 36.2% 
decrease in tumor lesion sum to 95.0 mm was observed.
Subject 004, a 74-year-old male who had a PR 
of 7 weeks with prior cisplatin/etoposide, had a PR (by 
investigator assessment) of 40 days (5.71 weeks) after 
Cycle 2; at baseline his sum of tumor lesions measured 
38.0 mm, and after Cycle 2 a 31.6% decrease in tumor 
lesion sum to 26.0 mm was observed.
Progression-free survival and overall survival
Progression-free survival (PFS) and overall survival 
(OS) are shown in Figure 3. Median PFS was 68 days 
(95% CI: 42,111), and median OS was 119 days (95% CI: 
89,178).
Disease control rate and duration of response
Disease control rate, based on investigator assessment, 
was 30.4% (95% CI: 13.2, 52.9). The rate was calculated 
based on 0 subjects with a complete response (CR), 4 subjects 
with a PR, and 3 subjects with confirmed stable disease (SD) 
≥4 cycles (confirmed in at least two assessments but no 
independent radiologic review performed), from all subjects 
who received study treatment (N = 23). The median time to 
response per RECIST v1.1 for subjects with a PR (N = 4) was 
49.5 days (range, 42-87 days).
Median duration of response per RECIST v1.1, 
based on investigator assessment, was 79.5 days (range, 
21-151 days) for subjects with a PR (N = 4) and was 
129.0 days (range, 81-256 days) for the subjects with SD 
(N = 7).
Analysis of archival tissue for c-Kit and RAD51 
expression
c-Kit expression in baseline tumor tissue
Archival FFPE tissue was available in 18 subjects 
for testing of c-Kit expression by immunohistochemistry 
(IHC). c-Kit staining (Figure 4) was present at high levels 
(H-score ≥100) in subject 008 (H-score 110/300, SD of 
256 days) and subject 023 (H-score 100/300, PR of 151 
days). Conversely, c-kit staining was present at low levels 
(score range, 10-20) in 5 subjects. c-Kit was not detected 
by IHC in the remaining 11 subjects.
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Partial response 7 (30)
Stable disease 11 (48)
Progressive disease 2 (9)
Unknown 3 (13)
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Table 2: Prior chemotherapy regimens by subject








































































Table 3: Last prior chemotherapy dose continued on study with amuvatinib



























































013 CisplatinEtoposide 100 (mg/m2)×3
147
588
014 CisplatinEtoposide 120 (mg/m2)×3
101
600








017 CisplatinEtoposide 100 (mg/m2)×2
84
336






















RAD51 immunohistochemistry of baseline tumor tissue
Archival FFPE tissue was available in 17 subjects 
for testing of RAD51 expression by IHC. RAD51 
staining (Figure 5) was present at high levels (score 
≥100) in 0 subjects and was present at low levels (score 
range, 10-20) in 11 subjects. In 6 subjects, RAD51 was 
not detected by IHC. Subject 008 (who had high c-Kit 
expression and a clinical benefit from the combination 
of amuvatinib + EP) had a RAD51 score of 50, which 
was among the highest. Beyond this observation, no 
association was apparent between baseline RAD51 and 
response to amuvatinib + EP.
Safety analyses
Amuvatinib 300 mg TID combined with EP 
chemotherapy was generally well tolerated and did 
Figure 1: Investigator assessment of best change from baseline in target tumor in modified intent-to-treat subjects. 
Table 4: Summary of best response to treatment (N = 23)
Disease control RECIST v1.1 by 
investigator assessment(n)
ConfirmedRECIST v1.1 by 
central radiology (n)
Duration of disease control, 
range (Days)
CR 0 0 --
PR 4a 2a 21-151b
SD 7 3c 81-256
PD 5 NA NA
NE 7 NA NA
CR = complete response; PR = partial response; SD = stable disease; PD = progressive disease; NE = not evaluable; NA = 
not applicable (progression was not required to be confirmed by central radiology assessment).
aTwo subjects (001 and 023) had a confirmed PR in at least two assessments that was confirmed by independent radiologic 
review. Two remaining subjects (002 and 004) did not meet the primary study endpoint of objective response (RECIST v1.1 
criteria).
bCalculation based on investigator assessment (n=4).
cThree subjects (008, 009, 012) had confirmed SDs in at least two assessments, but no independent radiologic review was 
performed.
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not appear to add to the expected toxicity of the EP 
combination. Five subjects had AEs that led to death 
<30 days after receiving the last dose of study treatment. 
These AEs included failure to thrive, respiratory failure, 
and chronic obstructive pulmonary disease, and were all 
considered not related to study treatment.
Table 5 lists treatment-emergent AEs reported with 
the highest incidence (≥10%) in the study. The most 
common Grade 3 and 4 AEs among the 23 treated subjects 
were neutropenia (11/23, 48%), thrombocytopenia (9/23, 
39%), anemia (5/23, 22%), fatigue (4/23, 17%), and 
leukopenia (4/23, 17%).
DISCUSSION
The primary objective of this study was to determine 
the effect of amuvatinib in combination with EP on overall 
objective response rate in subjects with platinum refractory 
Figure 2: CT scans of confirmed responders. Tumors indicated by arrows. (A) Subject 001 (67-yr-old female) Subject 001 entered 
the study with extensive-stage disease after previously receiving six cycles of prior chemotherapy with carboplatin/etoposide over a 15-
week period (total dose, carboplatin 3746 mg; etoposide 2964 mg). Her best response to prior therapy was SD of unknown duration. She 
also previously received two doses of palliative radiation therapy: 4500 rad to the right lung, and 3000 rad to the brain. After enrollment 
into the study, she received six cycles of study drug over an 18-week period, along with continuation of her last prior EP cycle (total 
dose, carboplatin, 660 mg, and etoposide, 420 mg) before beginning amuvatinib and had a best response of PR (119 days) in at least two 
assessments confirmed by independent radiologic review. (B) Subject 023 (52-yr-old male) Subject 023 entered the study with extensive-
stage disease after previously receiving six cycles of cisplatin/etoposide over a 16-week period with a best response of SD of four months’ 
duration. He also previously received two doses of palliative radiation therapy: 7500 rad to the right hilar mass and mediastinal lymph 
nodes, and 2500 rad to the right supraclavicular area. After enrollment into the study, he received six cycles of study drug over a 19-week 
period along with continuation of his last prior EP cycle (total dose, cisplatin 127 mg, and etoposide, 765 mg) before beginning amuvatinib 
and had a PR (151 days) in at least two assessments confirmed by independent radiologic review.
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SCLC. Although amuvatinib in combination with EP 
showed an ORR of 17.4% (PR by investigator assessment) 
and a disease control rate of 30.4% in this population of 
patients with SCLC, the regimen failed to meet the pre-
specified efficacy threshold to justify further evaluation.
Our observed ORR was greater than that observed 
previously in patients with SCLC who were administered 
topotecan, the only drug currently approved for second-
line treatment of SCLC. Ardizzoni et al [6] observed an 
ORR of 6.4% with topotecan administered as a 30-min 
infusion at 1.5 mg/m2/dose for five consecutive days in 
patients with refractory SCLC. Similarly, Perez-Soler 
et al [15] observed partial remissions in 3/32 etoposide-
refractory patients (11%) administered topotecan at 1.25 
mg/m2/dose over 30 min for five days every 21 days. In 
addition, a meta-analysis of results of clinical trials of 
investigational agents in relapsed SCLC showed an ORR 
of 17.9%, with a higher response rate of 27.7% (range, 
0%-77%) for sensitive SCLC versus 14.8% (range, 0%-
70%) for refractory patients; P = 0.0001 [16].
The safety profile of amuvatinib is consistent with 
previously reported results of manageable toxicity [14], 
and results from the current study provide additional 
support for the safety and tolerability of amuvatinib in 
combination with EP chemotherapy.
Nonclinical studies have shown RAD51 to be a 
potential predictor of tumor resistance in SCLC treatment 
[10]. Previous human studies have shown decreased 
RAD51 expression in skin biopsies from patients with 
advanced solid tumors who were treated with single-agent 
amuvatinib [13] as well as with amuvatinib in combination 
with standard therapy regimens [14]. However, we did 
not observe in the current study an association between 
baseline RAD51 levels and response to amuvatinib + 
EP. This may be due to the limited number of samples 
available for examination as well as the small number 
of patients who experienced clinical benefit in terms of 
objective response and durable control of disease.
The highest c-Kit scores were observed in two 
subjects with durable disease control to the combination 
of amuvatinib + EP: one with a PR of 151 days, the other 
with SD of 256 days. Of the 18 evaluable patients, 2/2 
with high c-Kit expression had durable disease control, 
whereas 2/16 patients with low c-Kit expression had 
similar responses to treatment. The limited number 
of subjects with available tissue and positive clinical 
outcome, as well as the single-arm study design, made it 
impossible to establish a true association between c-Kit 
expression and benefit of amuvatinib in combination with 
EP. However, previous studies have identified higher c-Kit 
Figure 3: Progression-free survival and overall survival (Kaplan-Meier): N = 23. 
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expression in SCLC cell lines when compared with non-
small cell lung cancer [2]. Furthermore, overexpression 
and activation of c-Kit in SCLC surgical specimens was 
demonstrated to be prognostic in SCLC [17-19]. Micke et 
al [17] showed that patients with c-Kit negative extensive 
stage SCLC have higher median survival rates and 
negligible response to old-generation chemotherapy (eg, 
cyclophosphamide and adriamycin combination, or single-
agent cyclophosphamide, adriamycin, or etoposide). 
Previous efforts to target c-Kit for therapeutic benefit 
in c-Kit expressing SCLC have been unsuccessful: in a 
single arm Phase 2 study, Schneider et al. [20] enrolled 
14 patients with c-Kit expressing tumors, of which eight 
patients with a PR to irinotecan/cisplatin received imatinib 
maintenance. No objective responses to imatinib were 
observed, although three patients achieved SD of 12-25 
weeks with median PFS and OS respectively of 4.3 months 
(95% CI, 2.9-4.8 months) and 7.8 months (95% CI, 5.7-
10.0 months). Similarly, Dy et al [21] reported results of a 
study (Simon 2-Stage design [22]) of imatinib in patients 
Figure 5: Baseline RAD51 tumor nuclear score. RAD51 nuclear expression was quantified using a 4-value intensity score (0 = 
none; 1 = weak; 2 = moderate; 3 = strong) and the percentage (0%-100%) of the extent of reactivity. A final expression score was obtained 
by multiplying the intensity and reactivity extension values (range, 0-300).
Figure 4: Baseline cytoplasmic c-Kit tumor IHC score. c-Kit staining was quantified by using a 4-value intensity score (none = 0; 
weak = 1+; moderate = 2+; strong = 3+) and the percentage (0%-100%) of the extent of reactivity. A final score was obtained by multiplying 
the intensity and reactivity extent values (range, 0-300). Subject 023 (PR of 151 days) and subject 008 (SD of 256 days) showed the highest 
H-score. (Archival FFPE tissue was available in 18 subjects. c-Kit was not detected by IHC in 11 subjects).
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with recurrent, refractory c-Kit-expressing SCLC. The 
study was terminated early following an interim analysis 
showing lack of efficacy. As amuvatinib is a multikinase 
inhibitor with activity against c-Kit and potentially other 
relevant SCLC targets in preclinical studies, it is tempting 
to ascribe the durable clinical benefit to amuvatinib + 
EP observed in our study in part to the high c-Kit scores 
obtained in those two subjects.
While future studies of amuvatinib in combination 
with DNA-damaging agents may be justified given the 
safety profile and nominal efficacy signal we observed, 
thoughtful patient selection will be important to ensure 
future studies are successful in demonstrating the clinical 
impact in SCLC and other cancer types.
MATERIALS AND METHODS
Study agent and regulatory information
Amuvatinib hydrochloride (C23H22ClN5O3S) is a 
fully synthetic carbothioamide that was administered in 
this study as lipid-suspension capsules containing drug 
product and excipients.
Seven study centers in the United States and one in 
Poland participated in the study. The study protocol was 
reviewed and approved by the governing institutional 
review boards (or ethics committees) overseeing research 
in human subjects at each center. Participating subjects 
provided written informed consent.
Table 5: Treatment-emergent adverse events in study subjects (N=23)
Preferred term N (%) Grade 3 and 4, n (%)
Thrombocytopenia 15 (65) 9 (39)
Neutropenia 14 (61) 11 (48)
Anemia 11 (48) 5 (22)
Fatigue 12 (52) 4 (17)
Diarrhea 9 (39) 1 (4)
Leukopenia 9 (39) 4 (17)
Nausea 9 (39) 0 (0)
Hypomagnesemia 9 (39) 0 (0)
Vomiting 7 (30) 0 (0)
Hyperglycemia 7 (30) 2 (9)
Hyponatremia 6 (26) 3 (4)
Hypokalemia 5 (21) 3 (4)
Decreased appetite 5 (21) 0 (0)
Dehydration 5 (21) 2 (9)
Dizziness 4 (17) 0 (0)
Peripheral sensory neuropathy 4 (17) 0 (0)
Dysgeusia 3 (13) 0 (0)
Hypocalcemia 3 (13) 1 (4)
QT prolongation 3 (13) 0 (0)
Edema peripheral 3 (13) 0 (0)
Urinary tract infection 3 (13) 0 (0)
Muscular weakness 3 (13) 0 (0)
Dysphagia 3 (13) 0 (0)
Hematuria 3 (13) 0 (0)
Respiratory failure 3 (13) 0 (0)
Cough 5 (21) 0 (0)
Dyspnea 5 (21) 1 (4)
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Subject population
Eligible subjects were males or females ≥18 years of 
age with histologically or cytologically confirmed SCLC 
and measurable SCLS according to the Response Evaluation 
Criteria in Solid Tumors (RECIST version 1.1) that met one 
of the following criteria: disease progression by RECIST at 
any time during initial or rechallenge with EP chemotherapy; 
relapse by RECIST within 90 days after completing EP 
chemotherapy; SD by RECIST as best response after at least 
two ≥21-day cycles of EP chemotherapy.
Subjects were required to have Eastern Cooperative 
Oncology Group (ECOG) performance status 0 to 2, 
adequate bone marrow (absolute neutrophil count [ANC] 
≥1,500/mL, platelet count ≥100,000 IU/L), renal function 
(serum creatinine <1.5 × upper limit of normal [ULN]), 
hepatic function (aspartate aminotransferase and alanine 
aminotransferase <2.5 × ULN, total bilirubin <1.5 × ULN), 
pulmonary function (O2 saturation >90% in room air), and 
cardiac function (no clinically significant ECG findings 
and left ventricular ejection fraction >50%). Subjects were 
required to have a measurable QTc interval (by Bazett’s 
or Fridericia’s formula) of <450 msec by 12-lead ECG 
and were also required to have electrolytes (magnesium, 
calcium, and potassium) within the normal limits of the 
institution at screening or corrected before the first day 
of amuvatinib dosing. Subjects could not have history 
of arrhythmias, angina pectoris, risk factors for Torsades 
de Pointes, ECG evidence of a myocardial infarction, or 
any Class 3 or 4 cardiac disease as defined by the New 
York Heart Association Functional Classification. Female 
subjects of childbearing potential could not be pregnant 
or breastfeeding and must have had a negative pregnancy 
test at screening.
Subjects excluded from participating were those who 
had previous exposure to amuvatinib; who came off prior 
chemotherapy due to toxicity; who have ongoing toxicity 
from prior treatment; who have mixed SCLC and non-small 
cell lung cancer, or large cell lung cancer. Subjects were 
excluded who had untreated, unstable, or symptomatic 
brain metastasis; history of a different malignancy within 
the last three years other than adequately treated and 
completely excised cervical cancer in situ, ductal carcinoma 
in situ, basal cell or squamous cell carcinoma of the skin. 
Subjects were also excluded if they had hypersensitivity to 
amuvatinib components of the drug product or any other 
agent associated with the study, were a poor medical risk, 
or had a life-threatening illness or other medical condition 
that might interfere with study outcomes. Patients must not 
have been treated with an investigational drug within three 
weeks of the first dose of study drug.
Study design
This was a Phase 2, multi-center, open-label, 
single-arm study of amuvatinib in combination with EP 
in subjects with extensive-stage or limited-stage SCLC 
who had not responded to standard treatment or who 
had relapsed after standard treatment (within 90 days 
of completing EP). The primary objective of the study 
was to assess overall objective response rate (complete 
response [CR] or partial response [PR]) to amuvatinib in 
combination with EP chemotherapy) per RECIST v1.1.
The primary study endpoint was overall objective 
response rate (CR or PR per RECIST v1.1); secondary 
endpoints were progression-free survival (PFS), overall 
survival (OS), disease control rate, duration of response, 
incidence and severity of adverse events (AEs), and 
assessment of exploratory biomarkers in selected subjects.
This study followed an optimal Simon 2-stage 
design [22] using the following parameters: α=10%, 
β=10%, p0=10% and p1=25%. Based on these parameters, 
three of 21 evaluable patients in Stage 1 were required 
to achieve confirmed objective response for the study to 
proceed to Stage 2 (accrual of additional 29 patients for a 
total sample size of 50 subjects).
Study procedures
Dosing
Subjects were administered 10 x 30 mg amuvatinib 
(300 mg total) lipid-suspension-filled capsules orally three 
times daily (TID) continually for 21 days (21-day cycles), 
taken in a seated position over a 30-minute period with 
water and, if feasible, with food. A 3-day amuvatinib run-
in period (±1 day) occurred in Cycle 1 prior to the 21-day 
treatment period.
The EP chemotherapy consisted of cisplatin or 
carboplatin, and etoposide (VP-16). Subjects received the 
same EP chemotherapy regimen (dose and schedule) as 
that on which they progressed or relapsed before study 
entry. Dosing started on Day 1, Cycle 1, after the three-
day run-in period of amuvatinib (±1 day) described above. 
Study treatment with chemotherapy and amuvatinib 
continued as long as the subject benefitted and no 
unacceptable toxicity occurred. No comparative treatment 
or placebo was used in this study.
Dose escalation was not allowed at any time during 
the study. Dose delay and/or adjustment of EP followed 
standard practice at the study center.
Supportive care
Appropriate hydration and supportive care 
(eg, antiemetics, antibiotics, or other growth factors) 
were permitted according to study center standards. 
Corticosteroids were permitted if the dose had been stable 
for at least two weeks before study entry. Medications 
with dysrhythmic potential were not recommended, and 
medications with the potential for QT prolongation were 




c-Kit is a target of amuvatinib and has been 
previously shown to be overexpressed in a subset of SCLC 
[23]. Therefore, we investigated whether tumor c-Kit 
expression levels corresponded with response in this study. 
To assay baseline c-Kit expression, formalin-fixed paraffin-
embedded (FFPE) sections from pre-treatment tumor 
biopsies (or archival samples from before study entry) were 
deparaffinized and rehydrated by heating overnight at 56°C, 
incubating 3×5 minutes in xylene, followed by three-minute 
washes in 100%, 95%, 70%, and 50% ethanol, followed by 
two washes for five minutes in deionized water. Antigen 
retrieval was achieved by bringing slides to a boil in 10 
mM sodium citrate buffer (pH 9.0), maintaining a sub-
boil for 30 minutes, and cooling at room temperature for 
20 minutes. Endogenous peroxidase activity was quenched 
by incubating sections in 3% H2O2/10% methanol for 15 
minutes. Sections were blocked for one hour in blocking 
solution, and 5% normal goat serum was diluted TBS-T 
(Tris Buffered Saline with Tween 20) at room temperature. 
Anti c-Kit primary antibody (A4502, DAKO, Carpenteria, 
CA) was diluted 1:400 in blocking solution and incubated 
for 1 hour at room temperature. Sections were washed three 
times in TBS-T before adding 1-3 drops Envision Dual 
Link+ (DAKO) and incubating in a humidified chamber for 
30 minutes at room temperature. Staining was developed 
using Signal Stain DAB (Cell Signaling Technology, 
Danvers, MA) chromogen before counterstaining with 
hematoxylin. Sections were finally dehydrated by washing 
twice in 95% ethanol, 100% ethanol and xylene, and then 
mounting coverslips with Permount (Fisher, Pittsburgh, 
PA). c-Kit staining (H-score) was quantified by using a 
four-value intensity score (0, none; 1+, weak; 2+, moderate; 
3+, strong) and the percentage (0%-100%) of the extent of 
reactivity. A final score was obtained by multiplying the 
intensity and reactivity extent values (range 0-300) [24]. 
A c-Kit score of ≥100 was considered high (ie, relatively 
higher-expressing and associated with more favorable 
clinical benefit), and ≤20 was considered low.
RAD51 immunohistochemistry of baseline tumor 
tissue
Proteomic analysis of preclinical SCLC models 
has previously shown overexpression of several DNA 
repair proteins in SCLC compared with non-small cell 
lung cancer (NSCLC) [2, 25]. Therefore, because the 
predicted mechanism of action of amuvatinib in platinum-
refractory SCLC was downregulation of RAD51 leading 
to sensitization to DNA-damaging agents (in this case, 
EP chemotherapy), we investigated whether baseline 
RAD51 levels were associated with patient responses. 
Immunohistochemical staining for RAD51 was performed 
on whole-section samples. Briefly, 4-μm FFPE tissue 
sections were deparaffined, hydrated, and processed in 
Leica BOND-MAX (Leica Microsystems Inc., Buffalo 
Grove, IL). Slides were incubated with the primary antibody 
(RAD51 (prediluted, Abcam, Cambridge, MA) 1:2). The 
antigen retrieval was performed with Leica Bond retrieval 
solution; the IHC reaction was performed according to 
standard protocol from Leica Bond, including 20 min of 
protein blocking, counterstained with hematoxylin, then 
dehydrated and mounted. RAD51 nuclear expression 
(H-score) was quantified as for c-Kit [24].
Statistical methods
All subjects who received any study treatment 
were included in the statistical analyses. Demographic 
and baseline characteristics were summarized using 
descriptive statistics.
Subject-reported and investigator-observed AEs 
were coded using the Medical Dictionary for regulatory 
Activities (MedDRA) version 14.0. AE severity was 
graded according to National Cancer Institute - Common 
Terminology Criteria for Adverse Events (CTCAE). AE 
incidence was summarized by MedDRA system organ 
class and preferred term, CTCAE grade, and relationship 
to study treatment.
Efficacy was assessed by the following:
• Objective response rate (ORR), defined as CR or 
PR according to RECIST v1.1 in two assessments at least 
four weeks apart and confirmed by independent radiologic 
review.
• Progression-free survival (PFS), defined as the 
number of days from the day the subject received the first 
dose of amuvatinib to the date of documented disease 
progression by RECIST v1.1 or death, whichever occurred 
first.
• Overall survival (OS), defined as the number of 
days from the day the subject received the first dose of 
amuvatinib to the date of death.
• Disease control rate, defined as the percentage 
of subjects who achieve a response of CR, PR, or SD ≥4 
cycles.
• Duration of response for CR or PR was 
determined from the earliest assessment of CR or PR 
until disease progression or death or last contact date, 
whichever occurred first. Duration of response for SD was 
computed from the day study treatment was first taken to 
the date of disease progression or death or last contact 
date, whichever occurred first.
ORR was summarized by number and percent of 
subjects with a CR or PR along with the 95% confidence 
interval (CI) based on a binomial distribution. Time 
to response was summarized for centrally confirmed 
responders (CR and PR) using mean, standard deviation, 
minimum, median, and maximum. Response rates and 
disease control rate were estimated along with the 95% 
CIs based on binomial distributions.
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Time-to-event endpoints were summarized using 
Kaplan-Meier analyses. PFS for subjects who withdrew 
from the study without documented disease progression 
(by RECIST v1.1) were censored on the day of withdrawal. 
Survival for a subject who was lost to follow-up was censored 
on the last date the subject could be confirmed living.
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